Lilly Acquires Adverum for One-Time Eye Disease Gene Therapy

Eli Lilly announces acquisition of Adverum Biotechnologies for up to $12.47 per share to advance Ixo-vec, a promising one-time gene therapy for age-related macular degeneration.